Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo

Frank Zela-Coila; Sonia Vizcarra-Jiménez; Alvaro Taype-Rondan

doi:10.35434/rcmhnaaa.2023.163.1948

Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo

Translated title of the contribution: Use of fosfomycin compared with ceftriaxone and meropenem for the treatment of urinary tract infections due to multidrug-resistant Escherichia coli (the FOREST study): Critically appraised article

Frank Zela-Coila^*, Sonia Vizcarra-Jiménez, Alvaro Taype-Rondan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Presentation: In this article, we present our critical assessment of a pragmatic clinical trial published in the Jama Network Open journal in the year 2022. Study conclusions: The study fails to demonstrate the non-inferiority of 4g of intravenous disodium fosfomycin every 6 hours over 60 minutes compared to ceftriaxone (1g of intravenous ceftriaxone every 24 hours over 2-4 minutes) or, if resistant to ceftriaxone, meropenem (1g of intravenous meropenem every 8 hours over 15-30 minutes). Critical comment: The article is relevant because bacterial resistance is currently of interest for the proper management of urinary tract infections. Therefore, alternatives that are not empirically used are being sought. However, the study has limitations such as not reaching the calculated sample size, having a low margin of noninferiority, and the lack of blinding in the intervention.

Translated title of the contribution	Use of fosfomycin compared with ceftriaxone and meropenem for the treatment of urinary tract infections due to multidrug-resistant Escherichia coli (the FOREST study): Critically appraised article
Original language	Spanish
Journal	Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
Volume	16
Issue number	3
DOIs	https://doi.org/10.35434/rcmhnaaa.2023.163.1948
State	Published - 2023

Access to Document

10.35434/rcmhnaaa.2023.163.1948

Cite this

Zela-Coila, F., Vizcarra-Jiménez, S., & Taype-Rondan, A. (2023). Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo. Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo, 16(3). https://doi.org/10.35434/rcmhnaaa.2023.163.1948

@article{3727ca37f9ec43b6b63f1e7cba830a84,

title = "Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoraci{\'o}n cr{\'i}tica del art{\'i}culo",

abstract = "Presentation: In this article, we present our critical assessment of a pragmatic clinical trial published in the Jama Network Open journal in the year 2022. Study conclusions: The study fails to demonstrate the non-inferiority of 4g of intravenous disodium fosfomycin every 6 hours over 60 minutes compared to ceftriaxone (1g of intravenous ceftriaxone every 24 hours over 2-4 minutes) or, if resistant to ceftriaxone, meropenem (1g of intravenous meropenem every 8 hours over 15-30 minutes). Critical comment: The article is relevant because bacterial resistance is currently of interest for the proper management of urinary tract infections. Therefore, alternatives that are not empirically used are being sought. However, the study has limitations such as not reaching the calculated sample size, having a low margin of noninferiority, and the lack of blinding in the intervention.",

author = "Frank Zela-Coila and Sonia Vizcarra-Jim{\'e}nez and Alvaro Taype-Rondan",

year = "2023",

doi = "10.35434/rcmhnaaa.2023.163.1948",

language = "Espa{\~n}ol",

volume = "16",

journal = "Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo",

issn = "2225-5109",

publisher = "Revista del Cuerpo M{\'e}dico del Hospital Nacional Almanzor Aguinaga Asenjo",

number = "3",

}

Zela-Coila, F, Vizcarra-Jiménez, S & Taype-Rondan, A 2023, 'Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo', Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo, vol. 16, no. 3. https://doi.org/10.35434/rcmhnaaa.2023.163.1948

Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo. / Zela-Coila, Frank; Vizcarra-Jiménez, Sonia; Taype-Rondan, Alvaro.
In: Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo, Vol. 16, No. 3, 2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST)

T2 - Valoración crítica del artículo

AU - Zela-Coila, Frank

AU - Vizcarra-Jiménez, Sonia

AU - Taype-Rondan, Alvaro

PY - 2023

Y1 - 2023

N2 - Presentation: In this article, we present our critical assessment of a pragmatic clinical trial published in the Jama Network Open journal in the year 2022. Study conclusions: The study fails to demonstrate the non-inferiority of 4g of intravenous disodium fosfomycin every 6 hours over 60 minutes compared to ceftriaxone (1g of intravenous ceftriaxone every 24 hours over 2-4 minutes) or, if resistant to ceftriaxone, meropenem (1g of intravenous meropenem every 8 hours over 15-30 minutes). Critical comment: The article is relevant because bacterial resistance is currently of interest for the proper management of urinary tract infections. Therefore, alternatives that are not empirically used are being sought. However, the study has limitations such as not reaching the calculated sample size, having a low margin of noninferiority, and the lack of blinding in the intervention.

AB - Presentation: In this article, we present our critical assessment of a pragmatic clinical trial published in the Jama Network Open journal in the year 2022. Study conclusions: The study fails to demonstrate the non-inferiority of 4g of intravenous disodium fosfomycin every 6 hours over 60 minutes compared to ceftriaxone (1g of intravenous ceftriaxone every 24 hours over 2-4 minutes) or, if resistant to ceftriaxone, meropenem (1g of intravenous meropenem every 8 hours over 15-30 minutes). Critical comment: The article is relevant because bacterial resistance is currently of interest for the proper management of urinary tract infections. Therefore, alternatives that are not empirically used are being sought. However, the study has limitations such as not reaching the calculated sample size, having a low margin of noninferiority, and the lack of blinding in the intervention.

UR - http://www.scopus.com/inward/record.url?scp=85185297930&partnerID=8YFLogxK

U2 - 10.35434/rcmhnaaa.2023.163.1948

DO - 10.35434/rcmhnaaa.2023.163.1948

M3 - Artículo

AN - SCOPUS:85185297930

SN - 2225-5109

VL - 16

JO - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo

JF - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo

IS - 3

ER -

Uso de fosfomicina comparado con ceftriaxona y meropenem para el tratamiento de las infecciones urinarias por Escherichia coli multirresistente (estudio FOREST): Valoración crítica del artículo

Abstract

Access to Document

Other files and links

Fingerprint

Cite this